Cargando…

FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients

BACKGROUND: Sarcoidosis is granulomatous disease of unknown origin affecting organ function and quality of life. The King’s Sarcoidosis Questionnaire (KSQ) serves as a tool to assess quality of life in sarcoidosis patients with general health and organ specific domains. A German translation has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Frye, Björn Christian, Potasso, Laura, Farin-Glattacker, Erik, Birring, Surrinder, Müller-Quernheim, Joachim, Schupp, Jonas Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643005/
https://www.ncbi.nlm.nih.gov/pubmed/34861850
http://dx.doi.org/10.1186/s12890-021-01761-7
_version_ 1784609790618501120
author Frye, Björn Christian
Potasso, Laura
Farin-Glattacker, Erik
Birring, Surrinder
Müller-Quernheim, Joachim
Schupp, Jonas Christian
author_facet Frye, Björn Christian
Potasso, Laura
Farin-Glattacker, Erik
Birring, Surrinder
Müller-Quernheim, Joachim
Schupp, Jonas Christian
author_sort Frye, Björn Christian
collection PubMed
description BACKGROUND: Sarcoidosis is granulomatous disease of unknown origin affecting organ function and quality of life. The King’s Sarcoidosis Questionnaire (KSQ) serves as a tool to assess quality of life in sarcoidosis patients with general health and organ specific domains. A German translation has been validated in a German cohort. In this study we assessed, whether clinical parameters influence KSQ scores. METHODS: Clinical data (e.g. lung function, organ impairment, serological parameters) for the German validation cohort were extracted from clinical charts and investigated by correlation and linear regression analyses. RESULTS: KSQ subdomain scores were generally lower in patients with respective organ manifestation or on current therapy. LUNG subdomain was significantly predicted by lung functional parameters, however for general health status, only FeV1 exerted significant influence. GHS was not influenced by serological parameters, but was significantly negatively correlated with body mass index (BMI). KSQ provides additional information beyond lung function, clinical or serological parameters in sarcoidosis patients. Notably, high BMI is significantly negatively associated with patients’ well-being as measured by KSQ-GHS. CONCLUSION: This observation may direct further studies investigating the effect of obesity on sarcoidosis-related quality of life and strategies to intervene with steroid-sparing therapies and measures of life style modifications. Trial registration This study was registered in the German Clinical Trials Register (reference number DRKS00010072). Registered January 2016. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01761-7.
format Online
Article
Text
id pubmed-8643005
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86430052021-12-06 FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients Frye, Björn Christian Potasso, Laura Farin-Glattacker, Erik Birring, Surrinder Müller-Quernheim, Joachim Schupp, Jonas Christian BMC Pulm Med Research BACKGROUND: Sarcoidosis is granulomatous disease of unknown origin affecting organ function and quality of life. The King’s Sarcoidosis Questionnaire (KSQ) serves as a tool to assess quality of life in sarcoidosis patients with general health and organ specific domains. A German translation has been validated in a German cohort. In this study we assessed, whether clinical parameters influence KSQ scores. METHODS: Clinical data (e.g. lung function, organ impairment, serological parameters) for the German validation cohort were extracted from clinical charts and investigated by correlation and linear regression analyses. RESULTS: KSQ subdomain scores were generally lower in patients with respective organ manifestation or on current therapy. LUNG subdomain was significantly predicted by lung functional parameters, however for general health status, only FeV1 exerted significant influence. GHS was not influenced by serological parameters, but was significantly negatively correlated with body mass index (BMI). KSQ provides additional information beyond lung function, clinical or serological parameters in sarcoidosis patients. Notably, high BMI is significantly negatively associated with patients’ well-being as measured by KSQ-GHS. CONCLUSION: This observation may direct further studies investigating the effect of obesity on sarcoidosis-related quality of life and strategies to intervene with steroid-sparing therapies and measures of life style modifications. Trial registration This study was registered in the German Clinical Trials Register (reference number DRKS00010072). Registered January 2016. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-021-01761-7. BioMed Central 2021-12-03 /pmc/articles/PMC8643005/ /pubmed/34861850 http://dx.doi.org/10.1186/s12890-021-01761-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Frye, Björn Christian
Potasso, Laura
Farin-Glattacker, Erik
Birring, Surrinder
Müller-Quernheim, Joachim
Schupp, Jonas Christian
FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
title FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
title_full FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
title_fullStr FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
title_full_unstemmed FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
title_short FeV1 and BMI influence King’s Sarcoidosis Questionnaire score in sarcoidosis patients
title_sort fev1 and bmi influence king’s sarcoidosis questionnaire score in sarcoidosis patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643005/
https://www.ncbi.nlm.nih.gov/pubmed/34861850
http://dx.doi.org/10.1186/s12890-021-01761-7
work_keys_str_mv AT fryebjornchristian fev1andbmiinfluencekingssarcoidosisquestionnairescoreinsarcoidosispatients
AT potassolaura fev1andbmiinfluencekingssarcoidosisquestionnairescoreinsarcoidosispatients
AT faringlattackererik fev1andbmiinfluencekingssarcoidosisquestionnairescoreinsarcoidosispatients
AT birringsurrinder fev1andbmiinfluencekingssarcoidosisquestionnairescoreinsarcoidosispatients
AT mullerquernheimjoachim fev1andbmiinfluencekingssarcoidosisquestionnairescoreinsarcoidosispatients
AT schuppjonaschristian fev1andbmiinfluencekingssarcoidosisquestionnairescoreinsarcoidosispatients